|
|
200 Middlesex Essex Turnpike, Ste 210
Iselin, NJ 08830 USA
phone:732- 404-1117
fax:732-404-1118
|
|
| Symbol |
SYMD |
| Exchange |
OTC |
| Founded |
1990 |
| Employees |
7 |
|
|
| www.synthemed.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Products to Reduce the Formation of Surgical Scar Tissue |
|
| Management |
| Richard L. Franklin, MD, Executive Chairman; Robert P. Hickey, President & CEO, Chief Financial Officer; Eli Pines, PhD, Vice President of Research & Chief Scientific Officer; Marc R. Sportsman, Vice President of Sales; John M. Benson, CPA, Controller; Gere S. diZerega, MD, Medical Director; John S. Hoffer, Director of Quality Systems and Regulatory Affairs; Corinne Mundin, Director, International Market Development |
| |
|
|
|
|
|
|
|
| Keywords |
| Cardiovascular, anti-adhesion, cardiology, Surgery Products, surgery, bioresorbable polymer, cardiac, heart surgery, scar tissues, adhesion, adhesions, orthopedic, spinal surgery, gynecologic surgery, general surgery, adv2007, j2008a, advamed |
|
|
|
| Description |
|
SyntheMed is a biomaterials company engaged in the development and commercialization of anti-adhesion and drug delivery products. The company is primarily focused on the advancement and expansion of product development programs based on its proprietary bioresorbable polymer technology. |
|
| Products / Services |
Synthemed is developing a portfolio of anti-adhesion products for use in different anatomic locations, led by REPEL-CV Bioresorbable Adhesion Barrier. REPEL-CV Adhesion Barrier is a thin film designed to be placed over the surface of the heart at the conclusion of an open heart surgical procedure to reduce the formation of post-operative adhesions. SinusShield is a bioresorbable polymer membrane indicated for use in patients undergoing nasal and sinus surgical procedures as a space- occupying stent to separate and prevent adhesions between mucosal surfaces. Other products under development focus on preventing or reducing post-operative adhesions subsequent to gynecologic, orthopedic and general surgical procedures and are in various stages of clinical trials and preclinical studies. A drug delivery product intended to reduce the onset of atrial fibrillation after open heart surgery is currently in preclinical development.
|
|
| Technology / Differentiation |
| Bioresorbable polymers are polymers that serve a temporary function in the body and then safely degrade into fragments which are either metabolized or eliminated via normal excretory routes. The company's proprietary line includes water soluble polymers, solid and injectable polymeric materials and thermal gels. The polymers can be reconstituted into forms of various viscosities depending on the temperature. |
|
| Market / Customers |
Adhesions are unavoidable byproducts of the trauma and bleeding that are associated with virtually all internal surgeries. They may cause such complications as infertility, bowel obstruction, chronic pain and restriction on joint mobility, in addition to the previously mentioned complications in cardiac surgery. The estimated annual market potential for anti-adhesion products ranges from $2-3 billion.
|
|
| Status |
| The lead product, REPEL-CV, is currently marketed internationally and is awaiting FDA approval in the United States. SyntheMed has also received FDA clearance to market SinusShield Adhesion Barrier in November 2008, a product intended for use in ENT procedures. The company is in discussions with prospective distribution partners for SinusShield. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members